Antiinflammatory activity of tissue plasminogen activator in the carrageenan rat footpad model

Free Radical Biology and Medicine

Volumn 22, Issue 6, 1997, Pages 985-988

  Stringer, Kathleen A ^a   Bose, Swapan K ^a   McCord, Joe M ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Edema; Inflammation; Neutrophils; Plasminogen activators; Superoxide anion

Indexed keywords

ALTEPLASE; CARRAGEENAN; PLASMINOGEN ACTIVATOR; STREPTOKINASE;

ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; EDEMA; HISTOPATHOLOGY; INFLAMMATION; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKOCYTE ACTIVATION; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARRAGEENAN; EDEMA; INFLAMMATION; MALE; NEUTROPHILS; RATS; RATS, SPRAGUE-DAWLEY; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ANIMALIA;

EID: 0031057621     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(96)00484-4     Document Type: Article

References (28)

1. Reich E. Activation of plasminogen: A general mechanism for producing local and extracellular proteolysis. Berlin R. D., Herrmann H., Lepow I. H., Tanzer J. M. Molecular basis of biological degradative processes. 1978;155-169 Academic Press, Inc, New York.
2. Hart D. A., Fritzler M. J. Regulation of plasminogen activators and their inhibitors in rheumatic diseases: New understanding and the potential for new directions. J. Rheumatol. 16:1989;1184-1191.
3. Hart D., Rehemtulla A. Plasminogen activators and their inhibitors: Regulators of extracellular proteolysis and cell function. Comp. Biochem. Physiol. 90B:1988;691-708.
4. Clemmensen I., Andersen R. B. The fibrinolytic system and its relation to inflammatory diseases. Semin. Arthritis Rheum. 11:1982;390-398.
5. Nachman R., Hajjar K., Silverstein R. et al. Interleukin-1 induces endothelial cell synthesis of plasminogen activator inhibitor. J. Exp. Med. 163:1986;1595-1600.
6. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med. 329:1993;673-682.
7. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N. Engl. J. Med. 329:1993;1615-1622.
8. Stringer, K. A.; Lindenfeld, J.; Repine, A. J.; Cohen, Z.; Repine, J. E. Tissue plasminogen activator (tPA) inhibits human neutrophil superoxide anion production in vitro. Inflammation (In press).
9. Engler R. L. Free radical and granulocyte mediated injury during myocardial ischemia and reperfusion. Am. J. Cardiol. 63:1989;19E-23E.
10. Engler R. L., Dahlgren M. D., Peterson M. A. et al. Accumulation of polymorphonuclear leukocytes during 3 h experimental ischemia. Am. J. Physiol. 25:1986;H93-H100.
11. Ferrari R., Ceconi C., Curello S., Cargnoni A., De Giuli F., Visioloi O. Occurrence of oxidative stress during myocardial reperfusion. Mol. Cell. Biochem. 111:1992;61-69.
12. Riesenberg K., Schlaeffer F., Katz A., Levy R. Inhibition of superoxide production in human neutrophils by combinations of heparin and thrombolytic agents. Br. Heart. J. 73:1995;14-19.
13. Mehta J. L., Mehta P., Lawson D. L., Herzbrun L. Tissue plasminogen activator and plasmin independently decrease human neutrophil activation. Life Sci. 45:1989;1665-1669.
14. Vinegar R., Truax J. F., Selph J. L. Quantitative studies of the pathway to acute carrageenan inflammation. Fed. Proc. 35:1976;2447-2456.
15. Vinegar R., Schreiber W., Hugo R. Biophasic development of carrageenin edema in rats. J. Pharmcol. Exp. Ther. 166:1969;96-103.
16. Vinegar R., Truax J., Selph J. L., Lea A. L., Johnston P. R. Quantitative in vivo studies of the acute actions of the anti-inflammatory drugs in the rat. Eur. J. Rheumatol. Inflamm. 1:1978;204-211.
17. Winter C. A., Flataker L. Reaction thresholds to pressure in edematous hindpaws and responses to analgesic drugs. J. Pharmacol. Exp. Ther. 150:1965;165-171.
18. Vinegar R., Truax J. F., Selph J. L., Johnston P. R., Venable A. L., McKenzie K. K. Pathway to carrageenan-induced inflammation in the hind limb of the rat. Fed. Proc. 46:1987;118-126.
19. Ando Y., Inoue M., Araki S., Morino Y. Inhibition of carrageenin-induced paw edema by a superoxide dismutase derivative that circulates bound to albumin. Biochim. Biophys. Acta. 1073:1991;374-379.
20. Salvemini D., Wang Z.-Q., Wyatt P. S., Bourdon D. M., Marino M. H., Manning P. T. et al. Nitric oxide: A key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br. J. Pharmacol. 118:1996;829-838.
21. Tbbe U., Tanswell P., Siefried E., Feuerer W., Scholtz K.-H., Herrmann K. S. Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. Am. J. Cardiol. 64:1989;448-453.
22. Clancy R. M., Abramson S. B. Nitric oxide: A novel mediator of inflammation. Proc. Soc. Exp. Biol. Med. 210:1995;93-101.
23. Deby C., Goutier R. New perspectives on the biochemistry of superoxide anion and the efficiency of superoxide dismutases. Biochem. Pharmacol. 39:1990;399-405.
24. Korninger C., Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb. Haemost. 46:1981;561-565.
25. Hybertson B. M., Stringer K. A., Cho O. J., Repine J. E. Tissue plasminogen activator reduces IL-1 induced lung injury. Am. J. Resp. Crit. Care. Med. 153:1996;A445.
26. Leff J. A., Baer J. W., Bodman M. E., Kirkman J. M., Shanley P. F., Patton L. M. et al. Interleukin-1 induced lung neutrophil accumulation and oxygen metabolite-mediated lung leak in rats. Am. J. Physiol. 266:1994;L2-L8.
27. Hajjar K. A., Hamel N. M., Harpel P. C., Nachman R. L. Binding of tissue plasminogen activator to cultured human endothelial cells. J. Clin. Invest. 80:1987;1712-1719.
28. Goa K. L., Henwood J. M., Stolz J. F., Langely M. S., Clissold S. P. Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction. Drugs. 39:1990;693-719.